This lab is helping fight the STI testing shortage caused by COVID-19
Share Article
MicroGenDX is a PCR and NGS lab with its own lab developed test (LDT) and is not impacted by the same shortages that are causing delays in STI testing elsewhere.
MicroGenDX Logo
MicroGenDX has over 11 years’ experience designing, and validating laboratory developed tests and mitigating risk in supply chains so that we are able to run the test you need when you need it. ORLANDO, Fla. (PRWEB) December 21, 2020 In an era when shortages abound, having options is invaluable. Worldwide, labs are facing a scarcity of supplies, as those needed to test for diseases such as sexually transmitted infections (STIs) must be diverted to Covid-19 testing. Enter MicroGenDX, a company specializing in qPCR + Next Generation Sequencing (NGS) microbial molecular diagnostics.a company that designs and set up its own tests and multiplex panels in-ho
Press release content from Newswire. The AP news staff was not involved in its creation.
World’s Largest Manufacturer of Rapid Antigen Tests Acquires California-Based BIOLAB
December 18, 2020 GMT
PASADENA, Calif. - December 17, 2020 - ( Newswire.com )
Innova Medical Group, Inc. (IMG), the world’s largest manufacturer of rapid antigen test kits, acquired California-based Biological Laboratory Inc. (BIOLAB), further strengthening IMG’s in-house diagnostic testing and research and development capability in the U.S.
Since 1998, this CLIA-certified clinical laboratory has shown spectacular success in endocrinology, cytology, toxicology, and molecular studies. Most recently BIOLAB played a key role in COVID-19 molecular (RT-PCR) and antibody (IgM/IgG) testing with its 24-hour turnaround on all routine testing and 2-hour STAT results in emergency situations. BIOLAB is recognized by the American Association of Bioanalysts (AAB), the College of American Pathologists
It looks like this was the result of either:
A mistyped address
A broken link on our site
A broken link on a search engine results page
A broken link on someone else s page
Some things to try:
Use the navigation menu at the top Most Read
email article
Should pathologists, technicians, and other behind-the-scenes staff who run COVID-19 tests be among the first to receive COVID-19 vaccines even though most don t have direct patient contact?
Yes, according to panelists from the College of American Pathologists at a media briefing Wednesday.
The briefing focused mainly on the broad range of challenges facing the laboratory community, such as reagent shortages and increased testing throughput. During one portion, however, speakers discussed risks faced personally by pathologists and technicians the tens of thousands of people who process specimens, maintain equipment, and manage testing supplies in the heat of the pandemic, but do so namelessly and unseen.